yahoo replacing "a", "first letter in the alhabet" with #$%$
Weird - when I post, #$%$ll the #$%$" in my text get repl#$%$#$%$ed by " #$%$ " #$%$s you #$%$#$%$n see in the text below.
If I t#$%$ke it into notep#$%$d #$%$nd do #$%$ se#$%$r#$%$h #$%$nd repl#$%$#$%$e, it then posts properly. Anyone else h#$%$ving th#$%$t problem???
hum#$%$n tri#$%$ls - if it w#$%$s #$%$ given th#$%$t these tri#$%$ls would work in hum#$%$ns, the m#$%$rket #$%$#$%$p
hum#$%$n tri#$%$ls - if it w##$%$ #$%$ given th#$%$t these tri#$%$ls would work in hum#$%$ns, the m#$%$rket #$%$#$%$p
No... RSV is worth approx $1 Billion a year - CGF166 is worth approx $5 Billion a year.
Although I would say that RSV has about 5 times better chance of it working... so in that way... they're about of equal value right now
Phase 1 studies, which primarily test for safety, require that a single patient be tested and monitored for safety before they move on to patient # 2, and possible/probable increase in dosage - a very slow process for first few patients.
However, Doug said that the very first dosage is enough to show efficacy if it works... that means that within appox 6 months, we may know if it works or not - my feeling is that... since Novartis will be first to know... they may well make an offer for $200M for the Atoh 1 technology alone and all it's patents - which is basically the amount of the milestone payments in aggregate, if it were to go to completion, that would save Novartis anywhere between $100M to $250M in royalty payments PER YEAR.
I'm guessing Doug will turn it down - If they make an offer... it will be a dead giveaway that it works.
Eventually it could easily bring in $5 Billion a year, @ 5% royalty that would be $250M a year pure profit in royalties - assuming 14M shares, that would/could be $17.85 per share in EARNINGS x 10 p/e = 178.50 per share... oh... minus $20K a year for a secretary to count the f#@en money!!! - IF IT WORKS
Pfizer Inc. (NYSEFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.
Holy s**t - 20K shares of IPCI now makes you a millionaire in 4 to 5 years... maybe sooner.
Fair buyout offer from Pfizer - $500 Million up front = 16.00 share + voucher good for $500 Million when/if Rexista gets FDA approval, + voucher good for $500 Million when/if Regabatin gets FDA approval - 1.5B total buyout to Pfizer - $48.00 share possible to present shareholders within 4 years.
assumes 30M fully diluted shares
I got all my nieces, nephews, my daughter and grandson all in on it -
They are all averaged in at around $3.60 - $3.70
popular??? hell yea!!! they can't thank me enough.
I hope you're short big time, and get your whole family to short it too a$$hole!!!
you're confused as to how this works - Selling puts at any price is a bullish position - I short would BUY the puts and give you a premim to do so.
I have sold many many PUTS - for instance the premium paid to me, for the July 7.50 PUT is $3.10 which makes my cost basis on the stock, if put to me at $4.40.
I have sold PUTS in many strike months and strike price - even this morning I sold some Oct 14 $12.50 PUTS and got $7.30 which makes my effective cost if put to me at $5.20.
Well, Well Well - The OCD basher finally answered my calling LOL... now would you respond to my previous question.
You've often referred to the Odidi's as goat herders - Now... since their accomplishments are so much greater than yours, - a dejected employee whose main accomplishment in life is to incessantly post drivel on an anonymous message board - and they, the Odidis, can buy you and sell you a thousand times over, - HOW MUCH LOWER THAN A GOAT HERDER DOES THAT MAKE YOU ???
Are you aware you are in serious need of help???
State your position on IPCI - are you long short or just sitting on your hands
LIAR - presentation and presenter both have stated that theirs is best in class resistance
I should add - I have 140K shares of IPCI and I believe it is the best risk reward I've come across in 25 years of investing in emerging biotechs. - This company has it all.
I've been saying from the beginning - the generics will keep the doors open and the first to file on Seroquel XR will bring in probably $100 Million in 2016 - but it's all about Rexista - best tamperproof technology out there , and Regabatin XR which is a once a day version of 3x a day Lyrica which sells $2.4 Billion a year .
It's all a matter of WHEN not IF. - Never said soon on Genvec and never said soon here - but if you buy 20,000 shares of IPCI - and forget about the noise here - you'll probably be a MILLIONAIRE in 3 to 5 years. - I expect to be a MULTI-MILLIONAIRE assuming IPCI is not bought out.
ROFLMFAO - I know the difference between LIES and inconvenient truths.
Post what I ACTUALLY said about Genvec - never said gnvc was SOON going to $200 you lying sack of shet - I said it has the potential to go to $200, still say so, and have been buying the hell out of it today. bought a boat load at 28 cents - made a small fortune - if their hearing technology works, $200 will be cheap.
You say - defend gregory who i think has brought a lot of good facts to this board -
ROFLMFAO - he was shouting get out get out at $1.70 - ROFLMFAO - you must have believed him and got out, ROFLMFAO - I bought around 100K shares then - probably the ones you sold.
You say - take facts wherever you can find them -
You're a lying sack of sheet trying to pass off lies as facts - you keep repeating that rexista's tamper proof technology has failed when instead it is THE BEST IN CLASS TECHNOLOGY OUT THERE incorporating ALL of the other technology together.
Below is a post from the brilliant bigot on this board from Nov 7, 2013 - at the time IPCI was at $1.70
Just how big of a MORON is this idiot getting 5 cents a post
gregory03.alan • Nov 7, 2013 7:17 PM Flag
1users liked this postsusers disliked this posts0Reply
ICEBERG Dead Ahead !!! DILUTION !!! SOS !!!
For Any New Investors Looking at IPCI this is a TERRIBLE TIME To Enter !!! Well ANY Time would be TERRIBLE With This Dr DILUTION Ready TO PAY BILLS ONCE AGAIN THRU THE DILUTION OF SHARE HOLDERS VALUE .... JUST LIKE THE PAST & 7 YEARS !!!! OMG !!! Please BEFORE Investing A Single Penny In IPCI you Must Fully Read The November 25, 2011 Press Release Putting $30 MILLION In Stock Printing into This Nigerian CEO Greasy Hands !!!
My feeling is that they will become a general contractor - selling the generics to "whoever" wants them for a cost plus mark up - if they were't partnered with PAR on focolin, they could now be selling all the focolin strenghts to TEVA, Mylan, Watson etc. who are having manufacturing problems
Strange that this release today had no negative effect on pps
Thursday, May 1, 2014 - 8:00am EDT
Pfizer Inc. (NYSE:PFE) presented results today from three pivotal studies of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules). One of the studies demonstrates a statistically significant difference in pain scores in patients with moderate-to-severe chronic low back pain receiving ALO-02 versus placebo. The other studies demonstrate lower abuse potential of ALO-02 in recreational opioid users by oral and intranasal routes when compared to immediate-release oxycodone. Data from these three studies were presented at the 33rd Annual Meeting of the American Pain Society (APS) in Tampa, Florida.
This was also released yesterday and has a direct bearing on Rexista
Purdue Pharma L.P. Submits NDA for Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated to Incorporate Abuse-Deterrent Properties
Data from Clinical Drug-liking Studies Also to be Presented at APS Today
Stamford, Conn. – April 30, 2014
The news release from yesterday may be the reason for the drop in pps.
I believe Rexista is once a day ... no?
Teva Reports Positive Results from Pivotal Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Moderate to Severe Chronic Low Back Pain
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties
JERUSALEM--(BUSINESS WIRE)--April 30, 2014--
It appears however that the National health service will not re-imburse the cost - I imagine they can pass this cost on to the patients ?
- The program requires drugmakers to foot the bill for any and all early access administrations -
After months of lobbying and speculation, the U.K. has unveiled its Early Access to Medicines Scheme, a program that will allow patients with serious diseases to get access to potentially lifesaving drugs before they're approved.
Starting next month, the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) will start taking applications from drugmakers who want to participate in the effort. Under the program, MHRA will first apply a so-called promising innovative medicines designation to successful applicants, and then, once it's satisfied with a drug's clinical data, the agency will green-light the treatment for preapproval use.
The program requires drugmakers to foot the bill for any and all early access administrations, a money-saving move for the U.K.'s National Health Service that isn't sitting very well with the industry. But Ian Hudson, head of MHRA, said pharma will be willing to shell out in exchange for the chance to cull real-world data and forge all-important physician relationships before a drug's proper launch.